secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001437749-24-034922
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica updates AIS trial protocol, delays interim readout to Q4 2025; Q3 R&D spend rises
--------------------------------------------------------------------------------

- Expanded ReMEDy2 trial to include thrombolytic non-responders; interim analysis sample size increased to 200 from 144.
- Top-line interim results now expected Q4 2025 (prior Summer 2025); interim analysis delayed.
- Q3 2024 R&D expenses $5.0M (up from $3.3M YoY); G&A flat at $1.9M.
- Cash, equivalents and investments $50.2M as of Sep 30, 2024; cash runway into Q3 2026.
- Preeclampsia Phase 2 IST received SAHPRA approval; first patient dosed; top-line Part 1A results expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924034922/0001437749-24-034922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924034922/dmtp20241113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer